CN103965175B - 4‑(取代苯氨基)喹唑啉类化合物、其制备方法及应用 - Google Patents
4‑(取代苯氨基)喹唑啉类化合物、其制备方法及应用 Download PDFInfo
- Publication number
- CN103965175B CN103965175B CN201310044776.9A CN201310044776A CN103965175B CN 103965175 B CN103965175 B CN 103965175B CN 201310044776 A CN201310044776 A CN 201310044776A CN 103965175 B CN103965175 B CN 103965175B
- Authority
- CN
- China
- Prior art keywords
- receptor tyrosine
- tyrosine kinase
- compound
- purposes
- formulas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CNc1c(*C2CC*CC2)cc(CN=I)c(C(NC2=CC(*)=C=C(*)C=C2)I)c1 Chemical compound CNc1c(*C2CC*CC2)cc(CN=I)c(C(NC2=CC(*)=C=C(*)C=C2)I)c1 0.000 description 2
- GNAKDRLFCSPELM-UHFFFAOYSA-N C(C1)C11COCCC1 Chemical compound C(C1)C11COCCC1 GNAKDRLFCSPELM-UHFFFAOYSA-N 0.000 description 1
- MSZFQBXQDALGLM-ULUSZKPHSA-N CNC(C=CC1I)=C[C@H]1Cl Chemical compound CNC(C=CC1I)=C[C@H]1Cl MSZFQBXQDALGLM-ULUSZKPHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
Description
测试物 | IC50(nM) |
化合物1 | 3 |
化合物2 | 47 |
化合物3 | 1 |
化合物4 | 20 |
化合物5 | 84 |
化合物6 | 210 |
阳性对照 | 3 |
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310044776.9A CN103965175B (zh) | 2013-02-05 | 2013-02-05 | 4‑(取代苯氨基)喹唑啉类化合物、其制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310044776.9A CN103965175B (zh) | 2013-02-05 | 2013-02-05 | 4‑(取代苯氨基)喹唑啉类化合物、其制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103965175A CN103965175A (zh) | 2014-08-06 |
CN103965175B true CN103965175B (zh) | 2017-12-22 |
Family
ID=51235229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310044776.9A Active CN103965175B (zh) | 2013-02-05 | 2013-02-05 | 4‑(取代苯氨基)喹唑啉类化合物、其制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103965175B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104119350B (zh) | 2013-04-28 | 2017-04-12 | 广东东阳光药业有限公司 | 氨基喹唑啉类衍生物及其盐和使用方法 |
CN104592212B (zh) * | 2014-12-31 | 2017-11-10 | 广东东阳光药业有限公司 | 一种阿法替尼中间体的制备方法 |
CN106045983A (zh) * | 2016-06-02 | 2016-10-26 | 苏州富士莱医药股份有限公司 | 阿法替尼的制备方法 |
US11111234B2 (en) * | 2016-08-12 | 2021-09-07 | Xuanzhu Pharma Co., Ltd. | Salt of a quinazoline derivative-like tyrosine kinase inhibitor and crystal form thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1731511B1 (de) * | 1999-06-21 | 2015-08-12 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
JP6437820B2 (ja) * | 2011-07-27 | 2018-12-12 | シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド | キナゾリン誘導体、その製造方法、中間体、組成物及びその適用 |
-
2013
- 2013-02-05 CN CN201310044776.9A patent/CN103965175B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103965175A (zh) | 2014-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2802296T3 (es) | Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK | |
CN105461695B (zh) | 嘧啶或三嗪衍生物及其制备方法和用途 | |
CN105237515B (zh) | 氘代嘧啶类化合物、其制备方法、药物组合物和用途 | |
CN105315259B (zh) | 吡啶胺基嘧啶衍生物、其制备方法及应用 | |
CN104530061B (zh) | 埃克替尼盐酸盐晶型、药物组合物和用途 | |
CN105073768A (zh) | Ras抑制剂及其用途 | |
CN102603743B (zh) | 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 | |
CN106029614A (zh) | 化合物的组合物及其用途 | |
CN102311449B (zh) | 棉酚衍生物在制备抗肿瘤药物中的应用 | |
CN103265560A (zh) | 棉酚/棉酮衍生物及其制备方法和抗肿瘤药物中的应用 | |
CN103965175B (zh) | 4‑(取代苯氨基)喹唑啉类化合物、其制备方法及应用 | |
CN108440583A (zh) | 一种新的硼酸衍生物及其药物组合物 | |
CN104910140A (zh) | 喹唑啉类化合物、其制备方法及应用 | |
CN107556361A (zh) | 裂环羽扇豆烷衍生物及其抗肿瘤用途 | |
CN104119329A (zh) | 新型苯并异硒唑酮修饰的吡咯甲酸酯取代的吲哚酮类化合物及其应用 | |
CN103732601B (zh) | 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用 | |
CN105566305B (zh) | 4-(取代苯胺基)喹唑啉衍生物二甲苯磺酸盐的多晶型物及其制备方法和用途 | |
CN104230912B (zh) | 喹啉衍生物、其制备方法及其用途 | |
CN105237533A (zh) | 四氢吡啶并[4,3-d]嘧啶类Hsp90抑制剂及其医药用途 | |
CN102531949A (zh) | 一种取代苯甲酰胺类化合物及其制备方法和用途 | |
CN108558865A (zh) | 一种以吡啶并[2,3-d]嘧啶结构为母核的衍生物及其制备方法和应用 | |
CN108586443A (zh) | 一种防治支气管肺癌的药物及其制备方法 | |
CN110283162B (zh) | 一种表皮生长因子受体抑制剂及其应用 | |
EP3012248B1 (en) | Substance having tyrosine kinase inhibitory activity and preparation method and use thereof | |
CN106554318A (zh) | 氘代二苯基氨基嘧啶化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190513 Address after: 250100 Xinlu Street 317, Jinan High-tech Zone, Shandong Province Co-patentee after: QILU ANTI (LINYI) PHARMACEUTICAL CO.,LTD. Patentee after: Qilu Pharmaceutical Co.,Ltd. Address before: 250100 Xinlu Street 317, Jinan High-tech Zone, Shandong Province Patentee before: Qilu Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address |
Address after: No. 243, North Industry Road, Licheng District, Jinan City, Shandong Province, 250108 Patentee after: Qilu Pharmaceutical Co.,Ltd. Patentee after: Shandong Anhong Pharmaceutical Co.,Ltd. Address before: 250100 Xinlu Street 317, Jinan High-tech Zone, Shandong Province Patentee before: Qilu Pharmaceutical Co.,Ltd. Patentee before: QILU ANTI (LINYI) PHARMACEUTICAL CO.,LTD. |
|
CP03 | Change of name, title or address |